Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae
Journal
Diagnostic Microbiology and Infectious Disease
Journal Volume
70
Journal Issue
1
Pages
150-153
Date Issued
2011
Author(s)
Abstract
For 244 patients with bacteremia due to extended-spectrum β-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae treated by ertapenem (73, 29.9%) or either imipenem or meropenem (171, 70.1%), the therapeutic efficacy was evaluated. Ertapenem therapy was effective for patients with ESBL-producing E. coli or K. pneumoniae bacteremia in terms of mortality and microbiological responses, as compared with imipenem or meropenem. ? 2011 Elsevier Inc.
SDGs
Other Subjects
ciprofloxacin; cotrimoxazole; ertapenem; extended spectrum beta lactamase; fluconazole; imipenem; linezolid; meropenem; polypeptide antibiotic agent; timentin; aged; antibiotic sensitivity; article; bacteremia; bacterial metabolism; controlled study; drug choice; drug efficacy; drug response; drug treatment failure; enzyme synthesis; Escherichia coli; female; Gram negative sepsis; human; Klebsiella pneumoniae; major clinical study; male; mortality; observational study; outcome assessment; priority journal; retrospective study; survival rate; treatment duration; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; beta-Lactams; Carbapenems; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Thienamycins; Treatment Outcome
Type
journal article